Found 38 clinical trials
FOURIER - Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk
FOURIER - Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk
- 268 views
- 25 Mar, 2021
- 1 location
ODYSSEY OUTCOME STUDY - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
ODYSSEY OUTCOME STUDY - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
- 100 views
- 25 Mar, 2021
- 1 location
Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease
cholesterol absorption inhibitors ezetimibe and PCSK9 inhibitor, large-scale clinical studies have been conducted to lower LDL cholesterol using these drugs. In this study, as in the statin study
- 0 views
- 12 Dec, 2021
- 2 locations
PCSK9 Inhibitor Treatment for Patients With SPG5
SPG5 patients, indicating that elevated levels of oxysterols might be key pathogenic factors in SPG5. Monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) have
- 9 views
- 16 Feb, 2022
- 1 location
Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction (PERFECT-AMI)
This is a prospect, multi-center, random study to investigate whether early offering PCSK9 inhibitor to acute myocardium infarction(AMI) can alleviate ventricular remodeling after primary
- 0 views
- 06 Jun, 2022
- 2 locations
Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography (MICROPROTECT)
Proprotein convertase subtilisin/kexin type 9 inhibitor monoclonal antibodies (anti-PCSK9) significantly reduce the serum LDL-C level, leading to a regression of the coronary epicardial plaque
- 0 views
- 06 Jun, 2022
- 1 location
Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients (ACAV)
, nicotinic acid or ezetimibe is not recommended in post-transplant scenario. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) increase availability has emerged as a novel drug tool for LDL
- 1 views
- 10 May, 2022
- 1 location
A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).
JS002 is a recombinant human anti-PCSK9 monoclonal antibody.The study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study in Chinese patients with
- 0 views
- 29 Apr, 2022
Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome (sICASBLM)
sICASBLM is a prospective controlled trial, to asses the impact of improving blood lipid management on clinical outcome of moderate to severe symptomatic intracranial atherosclerotic stenosis patients (LDL-C>1.8mmol/L) without endovascular therapy.
- 0 views
- 15 Jun, 2022
- 1 location
HYPOCHOL : A Genetically-based Strategy to Identify New Targets in Cholesterol Metabolism (HYPOCHOL)
The aim of this study is to identify new targets in cholesterol metabolism thanks to a genetically-based strategy.
- 0 views
- 24 Feb, 2022
- 1 location